Meet the experts

Meet the experts

CSU can be a debilitating disease, leading to a significantly reduced quality of life. In this "Meet the Expert" interview, Prof Dr. Maurer describes the impact CSU has on patients' lives, and shares his experience with Xolair.


Model is a hypothetical patient profile, for illustrative purposes only.

*Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients

Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.

Xolair® is also available as a lyophilized formulation

References: 1. Maurer M, et al. N Engl J Med 2013;368:924-935.  2. Xolair® Summary of Product Characteristics 2016.

NP4 code: GLDEIM/IGE025E/0181

Terms of use - Privacy policy - About cookies - Cookie Settings - This site is intended for a global audience.

© 2017 Novartis Pharma